Market research
 

THET PAING SOE’S operating culture alongside talented, well-trained and experienced personnel, our sales team has steered its course through vast network of distribution pipelines throughout Myanmar.



On a regular basis, our professional sales representatives visit our customers to fulfill their needs not only by collecting orders but also by sharing useful and updated information as well.

Regulatory Affairs
• Regulatory Affairs services
• Updated laws and health regulations
• PV reports


We can handle and provide Regulatory Affairs services to our valued partners who are in need. In addition, updated laws and health regulations and Pharmacovigilance reports could also be provided by our Regulatory Affairs Department.

 

 
 
Marketing Management

THET PAING SOE has its core marketing team with enough knowledge & skills through which it can provide all clinicians with complete, accurate, comprehensive and impartial information regarding pharmaceuticals.

Market research
 


As part of the requirements of marketing management, we conduct market research in order to make sure understanding of the market situation and consumer’s behavior.
Nationwide Distribution
 


We have our own wholesales & retail sales outlets in Yangon & Mandalay. Through these outlets as well as our Van Sales, we offer a nationwide distribution designed to cover important parts of the country.

We provide the efficient delivery service within 24 hours after receiving an order and also serve an urgent delivery in order to fulfill customers’ special needs.

Logistics
  • • Application for Import License
  • • Customs clearance
  • • Payment remittance
All importation procedures: Application of IL at the Ministry of Commerce, Customs clearance on the product arrival and payment remittance to the related banks are performed by our Logistics Team.
 

TRIMOVAX

trimovax

CONTENTS

Live attenuated measles, mumps and rubella virus.

PRESENTATION

Vial (freeze-dried powd for susp for inj) 1 dose + syringe 0.5 mL (diluent).

DESCRIPTION

Each dose of vaccine contains measles virus (Schwarz strain) cultivated on primary culture of chicken embryo cells at least 1000 CCID50, mumps virus (Urabe AM-9 strain) cultivated in embryonated hen eggs at least 5000 CCID50, rubella virus (Wistar RA 27/3M strain) activated on human diploid cells at least 1000 CCID50. It also contains human albumin for lyophilization and water for injections 0.5 mL as diluent.

*CCID50=TCID50=cell culture infectious dose 50%.

Trimovax is generally a homogenous pellet varying from yellow to pinkish beige.

After reconstitiution with the provided diluent, Trimovax is a clear solution varying from yellow to pinkish yellow.

INDICATIONS

Combined prevention of measles, mumps and rubella, from 12 months of age in children of both sexes.

DOSAGE & ADMINISTRATION

The 1st injection is administered from 12 months of age. A 2nd injection is recommended between 3 and 6 years.

Trimovax should be administered by SC or IM route.

Any reconstituted vaccine should be used immediately.

CONTRAINDICATIONS

History of severe hypersensitivity to any component of Trimovax or following a previous administration of Trimovax or a vaccine containing the same components or constituents (see Warnings).

Intramuscular route should not be administered for individuals with bleeding disorders eg, hemophilia or thrombocytopenia or malignant diseases.

Trimovax should not be administered to anyone with congenital or acquired immune deficiency impairing cellular immunity, including immunosuppressive therapies eg, chemotherapy, high doses of systemic corticosteroids given generally for ³14 days.

Use in pregnancy: As with all live attenuated vaccines, pregnancy constitutes a contraindication.

Immunization of women of childbearing age may only be carried out after checking that the woman is not pregnant. Pregnancy should be avoided 2 months following administration of the vaccine.

WARNINGS

In the case of individuals receiving immunosuppressive treatment, a 3-month delay after the end of the treatment should be observed before vaccine administration.

The immunization of women in childbearing age may be carried out only after checking that the woman is not pregnant (see Use in pregnancy under Contraindications).

Neomycin is used in the manufacturing process of Trimovax. As each dose may contain residual amounts of neomycin (<25 mcg/dose), caution must be exercised when Trimovax is administered to subjects with hypersensitivity to this antibiotic (and other antibiotic of the same class).

As each dose may contain residual amounts of ovalbumine (<1 mcg/dose), caution must be exercised when the vaccine is administered to subjects with true egg allergy.

Generally, vaccination must be postponed in cases of moderate or severe febrile and/or acute disease or severe infections.

Caution must be exercised when the vaccine is administered to subjects with convulsion history.

Recent injection of immunoglobulins (see Interactions).

PRECAUTIONS

Do not inject via the intravascular route.

Avoid contact between the vaccine and disinfectant products used for cleaning the injection site since they may inactivate the vaccine viruses.

As with all injectable vaccines, supervision and adrenaline used for the control of immediate allergic reactions must be available in case of an anaphylactic event following administration of the vaccine.

Use in lactation: Trimovax is not contraindicated in lactation.

ADVERSE REACTIONS

Based on data gathered from Trimovax post-marketing surveillance, the reported reactions are as follows: The adverse events are ranked under headings of frequency, using the following convention: Rare: 0.01% and 0.1%; very rare: 0.01%, including isolated reports.

General Disorder and Administration Site Conditions: Rare: Pain, induration, nodule, local urticaria, febrile reaction (pyrexia).

Skin and Subcutaneous Tissue Disorders: Rare: Lymphadenopathy. Very Rare: Erythematous or maculopapular rash.

Blood and Lymphatic System Disorders: Very Rare: Thrombocytopenic purpura, thrombocytopenia with a risk of haemorrhage in severe cases (1/100,000 doses).

Immune System Disorders: Very Rare: Allergic reaction including urticaria and face oedema.

Respiratory, Thoracic and Mediastinal Disorders: Very Rare: Rhinopharyngeal and cough.

Nervous System Disorders: Very Rare: Meningitis, meningoencephalitis, febrile convulsion.

Infections and Infestations: Very Rare: Orchitis.

Musculoskeletal and Connective Tissue Disorders: Very Rare: Arthralgia.

INTERACTIONS

In order to avoid neutralization of the attenuated viruses contained in the vaccine, vaccination must generally not be performed within 3 months of injection of human immunoglobulins or blood products containing immunoglobulins eg, blood or plasma.

For the same reason, immunoglobulins should not be administered for 2 weeks following immunization. To prevent the potential risk of interference, a 4-week delay should be observed before and after injection of any live attenuated vaccine.

Tuberculin tests may transiently show false negative results subsequent to vaccination.

STORAGE

Store between 2°C and 8°C. Protect from light.

Shelf-Life: 24 months.